Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1819 in Adolescents With Severe Atopic Dermatitis
NCT07309055Phase 3Recruiting
- Sponsor
- Hengrui Therapeutics
- Start
- Mar 2026
- Primary completion
- Nov 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of SHR-1819 in atopic dermatitis (AD), sponsored by Hengrui Therapeutics. Started Mar 2026; status: recruiting.
02
Drugs
SHR-1819
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07309055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07309055.